CA3228411A1 - Sulfonamide derivative, preparation method therefor and medical use thereof - Google Patents

Sulfonamide derivative, preparation method therefor and medical use thereof Download PDF

Info

Publication number
CA3228411A1
CA3228411A1 CA3228411A CA3228411A CA3228411A1 CA 3228411 A1 CA3228411 A1 CA 3228411A1 CA 3228411 A CA3228411 A CA 3228411A CA 3228411 A CA3228411 A CA 3228411A CA 3228411 A1 CA3228411 A1 CA 3228411A1
Authority
CA
Canada
Prior art keywords
general formula
cancer
compound represented
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228411A
Other languages
English (en)
French (fr)
Inventor
Xiaomin Zhang
Weimin Hu
Feng He
Weikang Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of CA3228411A1 publication Critical patent/CA3228411A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3228411A 2021-08-10 2022-08-10 Sulfonamide derivative, preparation method therefor and medical use thereof Pending CA3228411A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110913249 2021-08-10
CN202110913249.1 2021-08-10
CN202111142090.4 2021-09-28
CN202111142090 2021-09-28
CN202111500231 2021-12-09
CN202111500231.5 2021-12-09
PCT/CN2022/111395 WO2023016484A1 (zh) 2021-08-10 2022-08-10 磺酰胺衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CA3228411A1 true CA3228411A1 (en) 2023-02-16

Family

ID=85200573

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3228411A Pending CA3228411A1 (en) 2021-08-10 2022-08-10 Sulfonamide derivative, preparation method therefor and medical use thereof

Country Status (10)

Country Link
US (1) US20250145637A1 (https=)
EP (1) EP4385989A4 (https=)
JP (1) JP2024529068A (https=)
KR (1) KR20240046530A (https=)
CN (1) CN117597341A (https=)
AU (1) AU2022325367A1 (https=)
CA (1) CA3228411A1 (https=)
MX (1) MX2024001777A (https=)
TW (1) TW202321263A (https=)
WO (1) WO2023016484A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201334A1 (en) * 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2025136811A1 (en) * 2023-12-18 2025-06-26 Ideaya Biosciences, Inc. Chemical compounds and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118556053A (zh) 2021-11-16 2024-08-27 英矽智能科技知识产权有限公司 赖氨酸乙酰基转移酶6a(kat6a)抑制剂及其用途
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂
KR20250006833A (ko) 2022-03-28 2025-01-13 아이소스테릭스, 인코포레이티드 라이신 아세틸 전이효소의 myst 계열의 억제제
KR20250143814A (ko) * 2023-02-10 2025-10-02 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 설폰아미드 유도체 결정 형태 및 이의 제조 방법
WO2024189598A2 (en) 2023-03-16 2024-09-19 Olema Pharmaceuticals, Inc. Acylsulfonamide kat6a inhibitors
AU2024290895A1 (en) 2023-07-04 2026-01-29 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Kat6 inhibitor
WO2025098417A1 (zh) * 2023-11-08 2025-05-15 再和医药科技（苏州）有限公司 磺酰胺类化合物及其应用
WO2025101942A1 (en) * 2023-11-10 2025-05-15 Prelude Therapeutics Incorporated Kat6 targeting compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
HU225047B1 (en) * 1991-03-28 2006-05-29 Eisai Co Ltd Heterocyclic-piperidin-derivatives, pharmaceutical compositions containing them and process for their production
WO2002074746A1 (en) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
KR100965021B1 (ko) * 2002-02-22 2010-06-21 바이엘 파마슈티칼스 코포레이션 과다증식성 질환 치료에 유용한 벤조푸란 및 벤조티오펜유도체
AU2006281803B9 (en) * 2005-08-18 2013-05-30 Genmab A/S Therapy with CD4 binding peptides and radiation
CN105492430B (zh) * 2013-03-15 2017-10-10 基因泰克公司 取代的苯并噁唑及其使用方法
WO2015102929A1 (en) * 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
JP6568926B2 (ja) * 2014-03-20 2019-08-28 カペラ セラピューティクス，インコーポレーテッド 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017218960A1 (en) 2016-06-17 2017-12-21 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
MX2020007131A (es) 2017-11-29 2021-01-08 Epizyme Inc Inhibidores de histona acetiltransferasa de la familia myst.
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
KR20210057767A (ko) * 2018-09-07 2021-05-21 치아타이 티안큉 파마수티컬 그룹 주식회사 Crbn단백질에 작용하는 삼환식 화합물
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
CA3137472A1 (en) 2019-04-25 2020-10-29 Bayer Aktiengesellschaft Acyl sulfonamides for treating cancer
DK4299135T3 (da) * 2019-06-18 2025-09-08 Pfizer Benzisoxazol-sulfonamid-derivater
US12545669B2 (en) 2019-06-19 2026-02-10 Pfizer Inc. Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201334A1 (en) * 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2025136811A1 (en) * 2023-12-18 2025-06-26 Ideaya Biosciences, Inc. Chemical compounds and uses thereof

Also Published As

Publication number Publication date
MX2024001777A (es) 2024-02-29
JP2024529068A (ja) 2024-08-01
AU2022325367A1 (en) 2024-02-08
WO2023016484A1 (zh) 2023-02-16
EP4385989A4 (en) 2024-12-18
CN117597341A (zh) 2024-02-23
KR20240046530A (ko) 2024-04-09
EP4385989A1 (en) 2024-06-19
US20250145637A1 (en) 2025-05-08
TW202321263A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
CA3228411A1 (en) Sulfonamide derivative, preparation method therefor and medical use thereof
CN115448910B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
JP6403172B2 (ja) ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用
JP2020510012A (ja) ヘテロアリール［４，３−ｃ］ピリミジン−５−アミン誘導体、その製造方法、およびその医薬の使用
CN114149423B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JP2023145547A (ja) Ｃｄ７３阻害剤、その製造方法と応用
TW201934554A (zh) 吡唑并[1,5-a][1,3,5]三<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 d10999.TIF" img-content="tif" orientation="portrait" inline="yes"></img>-2-胺類衍生物、其製備方法及其在醫藥上的應用
TW202102505A (zh) 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用
WO2020011220A1 (zh) 杂芳基类衍生物、其制备方法及其在医药上的应用
KR20260006574A (ko) Kcc2 강화제 및 이의 용도
CN112996783B (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
JP7793763B2 (ja) Ｔｙｋ２／ｊａｋ１シュードキナーゼドメイン阻害剤としての化合物ならびに合成および使用方法
CA3060390A1 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN107428762B (zh) 酞嗪酮衍生物、其制备方法及用途
AU2024319888A1 (en) Heteroaryl compound, preparation method therefor, and use thereof in medicine
CN115611877A (zh) 磺酰胺类化合物、其制备方法及其在医药上的应用
JP2023536442A (ja) オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用
CN115073472A (zh) 稠合二环类化合物、其制备方法及其在医药上的应用
CN113754678A (zh) 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用
CN115835863B (zh) 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用
CN110684020B (zh) 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
CN118791498A (zh) 四环类化合物、其制备方法及其在医药上的应用
CN118978521A (zh) 并环化合物制备方法及应用
HK40029610B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250725

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250828